AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Neuropace Inc (NASDAQ:NPCE)
11.71 USD
+0.480 4.274%Sponsored Reports
Loading...
| Previous Close (in USD) | 11.23 |
|---|---|
| Change | +0.480 4.274% |
| 52 W H/L (in USD) | 18.150/3.800 |
| EBITDA (in USD) | -26.231M |
| PE Ratio | -- |
| Volume | 386931 |
| Diluted Eps TTM | -1.18 |
| Total Assets (in USD) | 107.651M |
|---|---|
| Total Liabilities (in USD) | 86.997M |
| Revenue TTM (in USD) | 69.073M |
| Cash (in USD) | 18.058M |
| Market Cap (in USD) | 216.624 M |
| Revenue Per Share TTM | 2.592 |
| Gross Profit TTM (in USD) | 32.493M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Neuropace Inc
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
455 North Bernardo Avenue, Mountain View, CA, United States, 94043
650-237-2700
Employees: 181
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Michael L. Favet | Pres, CEO & Director | 1970 |
| 2. | Ms. Irina Ridley | Gen. Counsel & Corp. Sec. | 1986 |
| 3. | Dr. Martha J. Morrell | Chief Medical Officer | 1957 |
| 4. | Ms. Rebecca L. Kuhn | CFO, VP of Fin. & Admin. and Assistant Sec. | 1961 |
| 5. | Ms. Chi Nguyen | VP of Marketing | 1977 |
| 6. | Mr. Mark S. Saxton | VP of Sales | 1965 |
| 7. | Ms. Irene Thomas | VP of HR | 1969 |
| 8. | Mr. Andre G. Marquette | Chief Commercial Officer | NA |
| 9. | Mr. Joel D. Becker | CEO, President & Director | 1968 |
| 10. | Ms. Rebecca L. Kuhn | CFO, VP of Finance & Administration and Assistant Secretary | 1961 |
Peers
Sector: Healthcare
Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ABT
Abbott Laboratories |
+0.303 0.222% | 135.78 | 37.150 | 23.148 | 4.666 | 4.975 | 4.878 | 19.381 |
|
SYK
Stryker Corporation |
+1.380 0.363% | 377.22 | 44.070 | 24.938 | 5.509 | 6.118 | 6.050 | 25.731 |
|
MDT
Medtronic PLC |
-0.314 0.355% | 88.21 | 26.600 | 15.873 | 3.354 | 2.083 | 3.897 | 14.117 |
|
BSX
Boston Scientific Corp |
+1.940 1.968% | 98.21 | 68.170 | 24.570 | 5.855 | 4.265 | 6.462 | 26.799 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -47.082M | -36.08M | -24.278M | -29.973M |
| Minority Interest | - | - | - | - |
| Net Income | -53.37M | -38.109M | -35.982M | -40.74M |
| Selling General Administrative | 51.341M | 38.961M | 27.628M | 30.201M |
| Gross Profit | 32.493M | 33.435M | 30.272M | 26.464M |
| Reconciled Depreciation | 2.987M | 0.296M | 0.312M | 0.421M |
| Ebit | -40.794M | -23.737M | -13.051M | -22.031M |
| Ebitda | -39.553M | -28.374M | -12.48M | -20.067M |
| Depreciation And Amortization | 1.241M | -4.637M | 0.571M | 1.964M |
| Operating Income | -40.794M | -23.737M | -13.051M | -22.031M |
| Other Operating Expenses | 86.314M | 68.92M | 54.189M | 59.003M |
| Interest Expense | 7.529M | 7.41M | 11.486M | 9.485M |
| Tax Provision | - | - | - | - |
| Interest Income | 1.578M | 0.448M | 0.041M | 0.261M |
| Net Interest Income | -5.951M | -6.962M | -11.445M | -9.224M |
| Income Tax Expense | 6.288M | 2.029M | 11.704M | 10.767M |
| Total Revenue | 45.52M | 45.183M | 41.138M | 36.972M |
| Total Operating Expenses | 73.287M | 57.172M | 43.323M | 48.495M |
| Cost Of Revenue | 13.027M | 11.748M | 10.866M | 10.508M |
| Total Other Income Expense Net | -6.288M | -12.343M | -11.227M | -7.942M |
| Net Income From Continuing Ops | -47.082M | -36.08M | -24.278M | -29.973M |
| Net Income Applicable To Common Shares | -47.082M | -36.08M | -24.05M | -29.973M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 107.651M | 114.106M | 133.562M | 55.95M | 21.095M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 2.737M | 3.111M | 2.319M | 1.179M | 1.251M |
| Total Liab | 86.997M | 79.329M | 60.059M | 203.782M | 150.445M |
| Total Stockholder Equity | 20.654M | 34.777M | 73.503M | -147.832M | -129.35M |
| Other Current Liab | 11.18M | 7.414M | 7.923M | 6.603M | 4.719M |
| Common Stock | 0.028M | 0.025M | 0.024M | 0.001M | 0.001M |
| Capital Stock | 0.028M | 0.025M | 0.024M | 0M | 0M |
| Retained Earnings | -503.809M | -470.853M | -423.771M | -387.691M | -363.641M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.49M | 134.308M | 0.873M | 0.025M |
| Cash | 18.058M | 6.605M | 19.187M | 26.39M | 4.123M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 16.229M | 10.976M | 9.301M | 9.595M | 75.148M |
| Current Deferred Revenue | 1.09M | - | - | - | 6.727M |
| Net Debt | 54.337M | 63.163M | 30.66M | 26.474M | 58.676M |
| Short Term Debt | 1.627M | 1.415M | - | 2.043M | 62.799M |
| Short Long Term Debt | - | - | - | 2.043M | 62.799M |
| Short Long Term Debt Total | 72.395M | 69.768M | 49.847M | 52.864M | 62.799M |
| Other Stockholder Equity | 524.435M | 506.713M | 363.96M | 239.826M | 234.29M |
| Property Plant Equipment | - | 1.064M | 0.603M | 0.515M | 0.81M |
| Total Current Assets | 92.719M | 97.714M | 132.816M | 54.562M | 20.26M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 48.396M | 70.804M | 96.397M | 11.689M | 0.969M |
| Net Receivables | 12.314M | 7.482M | 7.091M | 8.395M | 6.017M |
| Long Term Debt | 56.954M | 52.913M | 49.847M | 50.821M | - |
| Inventory | 11.214M | 9.712M | 7.822M | 6.909M | 7.9M |
| Accounts Payable | 2.332M | 2.147M | 1.378M | 0.949M | 0.903M |
| Accumulated Other Comprehensive Income | 0M | -1.108M | -0.272M | 0.033M | 0.001M |
| Non Currrent Assets Other | 0.402M | 0.49M | 0.143M | 0.873M | 0.025M |
| Non Current Assets Total | 14.932M | 16.392M | 0.746M | 1.388M | 0.835M |
| Capital Lease Obligations | 15.441M | 16.855M | - | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | 24.4M | -85.012M | -10.705M | 4.082M |
| Total Cashflows From Investing Activities | 23.797M | -85.396M | -10.767M | 3.618M |
| Total Cash From Financing Activities | 0.49M | 102.526M | 55.009M | 21.37M |
| Net Income | -47.082M | -36.08M | -24.278M | -29.973M |
| Change In Cash | -12.582M | -7.447M | 22.633M | -0.038M |
| Begin Period Cash Flow | 19.309M | 26.756M | 4.123M | 4.161M |
| End Period Cash Flow | 6.727M | 19.309M | 26.756M | 4.123M |
| Total Cash From Operating Activities | -36.869M | -24.577M | -21.609M | -25.026M |
| Depreciation | 2.987M | 0.296M | 0.312M | 0.421M |
| Other Cashflows From Investing Activities | - | - | - | - |
| Dividends Paid | - | - | - | - |
| Change To Inventory | -2.133M | -1.156M | 0.672M | -1.638M |
| Sale Purchase Of Stock | 0.549M | 106.616M | - | - |
| Other Cashflows From Financing Activities | -0.406M | -2.473M | 97.129M | 3.618M |
| Capital Expenditures | 0.603M | 0.384M | 0.062M | 0.468M |
| Change In Working Capital | -4.788M | 0.368M | -2.067M | 0.009M |
| Other Non Cash Items | 3.665M | 1.073M | 2.858M | 4.019M |
| Free Cash Flow | -37.472M | -24.961M | -21.671M | -25.494M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 694155 |
| 2. | Fidelity Small Cap Growth | 1 year ago | 337866 |
| 3. | Xtrackers MSCI World Swap ETF 1C | 1 year ago | 241429 |
| 4. | Xtrackers S&P 500 Swap ETF 1C | 1 year ago | 170827 |
| 5. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 149349 |
| 6. | Fidelity Small Cap Growth K6 | 1 year ago | 127531 |
| 7. | Fidelity Extended Market Index | 1 year ago | 58056 |
| 8. | Pleiades Small Cap Equity A | 1 year ago | 39308 |
| 9. | EAM Ultra Micro Cap | 1 year ago | 36567 |
| 10. | Bridgeway Ultra-Small Company Market | 1 year ago | 28400 |
| 11. | BlackRock Extended Mkt Composite | 1 year ago | 22694 |
| 12. | iShares Micro-Cap ETF | 1 year ago | 22651 |
| 13. | BlackRock Extended Equity Market K | 1 year ago | 19806 |
| 14. | Fidelity Total Market Index | 1 year ago | 17974 |
| 15. | Acuitas US Microcap Strategy | 1 year ago | 17195 |
| 16. | Fidelity Nasdaq Composite Index | 1 year ago | 16625 |
| 17. | LUX IM Global Medtech HX | 1 year ago | 15868 |
| 18. | Fidelity Series Total Market Index | 1 year ago | 14160 |
| 19. | Vanguard Balanced Index Inv | 1 year ago | 14122 |
| 20. | Vanguard Instl Ttl Stk Mkt Idx InstlPls | 1 year ago | 13081 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Orbimed Advisors, LLC | 1 year ago | 4003967 |
| 2. | Morgan Stanley - Brokerage Accounts | 1 year ago | 2460716 |
| 3. | Soleus Capital Management, L.P. | 1 year ago | 2433168 |
| 4. | Nantahala Capital Management, LLC | 1 year ago | 2347354 |
| 5. | Kent Lake Capital LLC | 1 year ago | 643629 |
| 6. | Millennium Management LLC | 1 year ago | 605713 |
| 7. | Vanguard Group Inc | 1 year ago | 488618 |
| 8. | FMR Inc | 1 year ago | 468081 |
| 9. | Geode Capital Management, LLC | 1 year ago | 115996 |
| 10. | Renaissance Technologies Corp | 1 year ago | 108325 |
| 11. | BlackRock Inc | 1 year ago | 86502 |
| 12. | Citigroup Inc | 1 year ago | 75688 |
| 13. | EAM Investors, LLC | 1 year ago | 66141 |
| 14. | Acadian Asset Management LLC | 1 year ago | 47215 |
| 15. | Susquehanna International Group, LLP | 1 year ago | 42285 |
| 16. | JANE STREET GROUP, LLC | 1 year ago | 36822 |
| 17. | Northern Trust Corp | 1 year ago | 35022 |
| 18. | Bridgeway Capital Management, LLC | 1 year ago | 33900 |
| 19. | State Street Corporation | 1 year ago | 33351 |
| 20. | Bank of America Corp | 1 year ago | 31905 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...